J. Nathan Davis

Statistics

Publications

Citations

1.5K

H-Index

Active since

1991

Affiliations

Louisiana State University Health Sciences Center Shreveport(Current)

St. Jude Children's Research Hospital

Mayo Clinic in Arizona

Louisiana State University

University of Iowa

J. Nathan Davis is an author at Louisiana State University Health Sciences Center Shreveport specializing in molecular biology, life sciences, and medicine.

Publications per year

1991–2020

Publications

The t(12;21) Translocation Converts AML-1B from an Activator to a Repressor of Transcription

Scott W. Hiebert, Wuhua Sun, J. Nathan Davis et al. · Molecular and Cellular Biology · 1996 · 278 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +13

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

Alex A. Adjei, Charles Erlichman, J. Nathan Davis et al. · PubMed · 2000 · 243 citations

Medicine, Oncology, Pharmacology +10

Gfi‐1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA‐sensitive mechanism

Laura L. McGhee, Josh Bryan, Liza T Elliott et al. · Journal of Cellular Biochemistry · 2003 · 121 citations

Life Sciences, Cell Biology, Molecular Biology +17

Comparison of potential markers of farnesyltransferase inhibition.

Alex A. Adjei, J. Nathan Davis, Charles Erlichman et al. · PubMed · 2000 · 119 citations

Medicine, Molecular Biology, Pharmacology +17

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

Alex A. Adjei, J. Nathan Davis, Laura M. Bruzek et al. · PubMed · 2001 · 96 citations

Medicine, Pharmacology, Cancer Pharmacology +9

1–5 of 21